Full metadata record
DC FieldValueLanguage
dc.creatorTadevosyan, K. (Karine)-
dc.creatorIglesias-García, O. (Olalla)-
dc.creatorMazo, M. (Manuel)-
dc.creatorProsper-Cardoso, F. (Felipe)-
dc.creatorRaya, Á. (Ángel)-
dc.date.accessioned2021-09-14T06:45:48Z-
dc.date.available2021-09-14T06:45:48Z-
dc.date.issued2021-
dc.identifier.citationTadevosyan, K.; Iglesias-García, O. (Olalla); Mazo-Vega, M. (Manuel María); et al. "Engineering and Assessing Cardiac Tissue Complexity". International Journal of Molecular Sciences. 22 (3), 2021, 1479es
dc.identifier.issn1422-0067-
dc.identifier.urihttps://hdl.handle.net/10171/61987-
dc.description.abstractCardiac tissue engineering is very much in a current focus of regenerative medicine research as it represents a promising strategy for cardiac disease modelling, cardiotoxicity testing and cardiovascular repair. Advances in this field over the last two decades have enabled the generation of human engineered cardiac tissue constructs with progressively increased functional capabilities. However, reproducing tissue-like properties is still a pending issue, as constructs generated to date remain immature relative to native adult heart. Moreover, there is a high degree of heterogeneity in the methodologies used to assess the functionality and cardiac maturation state of engineered cardiac tissue constructs, which further complicates the comparison of constructs generated in different ways. Here, we present an overview of the general approaches developed to generate functional cardiac tissues, discussing the different cell sources, biomaterials, and types of engineering strategies utilized to date. Moreover, we discuss the main functional assays used to evaluate the cardiac maturation state of the constructs, both at the cellular and the tissue levels. We trust that researchers interested in developing engineered cardiac tissue constructs will find the information reviewed here useful. Furthermore, we believe that providing a unified framework for comparison will further the development of human engineered cardiac tissue constructs displaying the specific properties best suited for each particular application.-
dc.description.sponsorshipResearch in the authors’ laboratories on this topic is supported by the Spanish Ministry of Economy and Competitiveness-MINECO (RTI2018-095377-B-100), Instituto de Salud Carlos III- ISCIII/FEDER (Red de Terapia Celular—TerCel RD16/0011/0024 and RD16/0011/0005; PI 19/01350), Gobierno de Navarra Departamento de Salud (GNª8/2019), co-funded by FEDER funds, European Union’s H2020 Program under grant agreement No 874827 (BRAV∃), AGAUR (2017-SGR-899), and CERCA Programme/Generalitat de Catalunya.-
dc.language.isoen-
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/874827/EU-
dc.relationAGAUR (2017-SGR-899)-
dc.rightsinfo:eu-repo/semantics/openAccess-
dc.subjectPluripotent stem cells-
dc.subjectCardiomyocytes-
dc.subjectCardiac tissue engineering-
dc.subjectHuman heart-
dc.subjectTissue maturation-
dc.titleEngineering and assessing cardiac tissue complexity-
dc.typeinfo:eu-repo/semantics/review-
dc.description.noteThis article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).-
dc.identifier.doi10.3390/ijms22031479-
dadun.citation.publicationNameInternational Journal of Molecular Sciences-
dadun.citation.startingPage1479-
dadun.citation.volume22-

Files in This Item:
Thumbnail
File
pdf.pdf
Description
Size
1.28 MB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.